Serologic markers of untreated celiac disease in Libyan children: antigliadin, antitransglutaminase, antiendomysial, and anticalreticulin antibodies.
BACKGROUND
There are, as yet, no data available about the incidence of celiac disease in Libya. The aim of this study was to test the occurrence of serologic markers in a group of Libyan children with positive clinical and histologic findings indicative of celiac disease diagnosis.


METHODS
Thirty-nine children with untreated celiac disease and 50 healthy school children, all younger than 14 years, were included in the study. Enzyme-linked immunosorbent assay for immunoglobulin G and immunoglobulin A (IgA) antigliadin, antitissue transglutaminase, and anticalreticulin antibodies was used to evaluate the serologic markers of the celiac patients. Immunoglobulin A antiendomysial antibodies were detected by indirect immunofluorescence using human umbilical cord tissue.


RESULTS
Clinical symptoms at presentation were weight loss (82%), abdominal distension (61.5%), diarrhea or steatorrhea (59%), pallor (41%), abdominal pain (20.5%), constipation (15%), vomiting (10%), and short stature (7.7%). Most of these symptoms disappeared after introduction of a gluten-free diet. Of 39 patients, only 23 (59%) were endomysium positive and positive also in all other serologic markers. The second group of patients with positive clinical and biopsy findings but antiendomysial antibody-negative findings was subdivided into two subgroups according to the IgA antigliadin antibody results. Individuals in the IgA gliadin-negative subgroup also lacked IgA autoantibodies.


CONCLUSIONS
The authors' findings stress the importance of serologic testing not only for screening but also for confirmation of celiac disease.
Ashabani
A
A
Department of Immunology and Gnotobiology, Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic. aashabani@hotmail.com
Errabtea
H
H
Shapan
A
A
Tuckova
L
L
Tlaskalova-Hogenova
H
H
D000293:Adolescent; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D015415:Biomarkers / Q000097:blood; D002135:Calcium-Binding Proteins / Q000276:immunology*; D037282:Calreticulin; D002446:Celiac Disease / Q000097:blood* / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology; D002648:Child; D004032:Diet; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D005903:Gliadin / Q000276:immunology*; D005983:Glutens / Q000008:administration & dosage; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D015994:Incidence; D007583:Jejunum / Q000473:pathology; D008002:Libya / Q000453:epidemiology; D008297:Male; D012261:Ribonucleoproteins / Q000276:immunology*; D011503:Transglutaminases / Q000276:immunology*
D001323:Autoantibodies; D015415:Biomarkers; D002135:Calcium-Binding Proteins; D037282:Calreticulin; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D012261:Ribonucleoproteins; D005983:Glutens; D005903:Gliadin; D011503:Transglutaminases